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Abstract
Cell cycle progression, including genome duplication, is orchestrated by cyclin-dependent kinases (CDKs). CDK activation
depends on phosphorylation of their T-loop by a CDK–activating kinase (CAK). In animals, the only known CAK for CDK2 and
CDK1 is cyclin H-CDK7, which is constitutively active. Therefore, the critical activation step is dephosphorylation of inhibitory
sites by Cdc25 phosphatases rather than unrestricted T-loop phosphorylation. Homologous CDK4 and CDK6 bound to
cyclins D are master integrators of mitogenic/oncogenic signaling cascades by initiating the inactivation of the central
oncosuppressor pRb and cell cycle commitment at the restriction point. Unlike the situation in CDK1 and CDK2 cyclin
complexes, and in contrast to the weak but constitutive T177 phosphorylation of CDK6, we have identified the T-loop
phosphorylation at T172 as the highly regulated step determining CDK4 activity. Whether both CDK4 and CDK6
phosphorylations are catalyzed by CDK7 remains unclear. To answer this question, we took a chemical-genetics approach
by using analogue-sensitive CDK7(as/as) mutant HCT116 cells, in which CDK7 can be specifically inhibited by bulky adenine
analogs. Intriguingly, CDK7 inhibition prevented activating phosphorylations of CDK4/6, but for CDK4 this was at least partly
dependent on its binding to p21cip1. In response to CDK7 inhibition, p21-binding to CDK4 increased concomitantly with
disappearance of the most abundant phosphorylation of p21, which we localized at S130 and found to be catalyzed by both
CDK4 and CDK2. The S130A mutation of p21 prevented the activating CDK4 phosphorylation, and inhibition of CDK4/6 and
CDK2 impaired phosphorylations of both p21 and p21-bound CDK4. Therefore, specific CDK7 inhibition revealed the
following: a crucial but partly indirect CDK7 involvement in phosphorylation/activation of CDK4 and CDK6; existence of
CDK4-activating kinase(s) other than CDK7; and novel CDK7-dependent positive feedbacks mediated by p21
phosphorylation by CDK4 and CDK2 to sustain CDK4 activation, pRb inactivation, and restriction point passage.
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Introduction
The cell cycle commitment at the restriction (R) point in G1
phase is initiated by inactivating phosphorylations of the central
cell cycle/tumor suppressor pRb by CDK4 and CDK6, which are
activated by D-type cyclins induced by mitogenic/oncogenic
signaling [1–3]. pRb phosphorylation is then maintained inde-
pendently of cyclins D, and hence of mitogens, by a positive
feedback loop linking pRb to E2F-dependent transcription of
cyclin E, which leads to CDK2 activation and further phosphor-
ylation of pRb [4]. This, together with other positive-feedback
circuits, such as E2F inducing its own transcription and the mutual
inhibition between cyclin E-CDK2 and p27Kip1, has been shown
to generate a bistable pRb-E2F switch to convert graded mitogen
inputs into all-or-none E2F responses and thus cell cycle commit-
ment [5]. The effects of the Cip/Kip CDK inhibitors p21 and p27
in this process are complex and remain much debated [6,7]. p21 is
the main transcriptional target involved in replicative senescence
and p53-dependent cell cycle inhibition in response to DNA
damage. But in unperturbed cell cycles, it is also transiently induced
bymitogenic stimuli during G1, before its required disappearance at
the G1/S transition [8]. While p21 inhibits CDK2 [9], it also plays
essential positive roles by stabilizing cyclin D-CDK4 complexes and
allowing their nuclear import [3,10]. How can p21 and p27 bind to
CDK4 complexes and either inhibit or not inhibit their activity is
poorly understood [3,6,8]. One debated possibility is related to
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different stoichiometries of the binding of these proteins to cyclin-
CDK complexes [10,11]. On the other hand, as first exemplified by
T187 phosphorylation of p27 [12], phosphorylations of Cip/Kip
proteins, including by oncogenic tyrosine kinases, have also
emerged as other potential mechanisms for CDK regulation [13–
17].
CDK4/6 activity is deregulated through various mechanisms in
many human tumors [18,19]. Such deregulation is crucial for
various oncogenic transformation processes [20–22] suggesting
that many cancer cells are addicted to high CDK4/6 activity
[19,23–25]. A CDK4/6 inhibitor (PD0332991 [24–29]) that
effectively halts tumor growth in preclinical models and in patients
is being tested in phase II clinical trials on various pRb-proficient
chemotherapy-resistant cancers.
Activation of CDK4/6 is a still poorly understood multistep
process that includes an activating phosphorylation in the T-loop
at T172 in CDK4 [30,31] and at T177 in CDK6 [32,33].
However, these crucial phosphorylations have been barely studied
because easy detection tools are unavailable. Despite constitutive
cyclin D expression, defective expression of INK4 CDK4/6
inhibitory proteins and frequent overexpression of cyclin E [34],
many tumor cells maintain at least partial regulation at the R
point. By using 2D-gel electrophoresis to separate the phosphor-
ylated forms of CDK4 and CDK6 bound to their regulatory
partners, we have identified the activating T172 phosphorylation
as the last, separately regulated, critical step of CDK4 activation in
such tumor cells [3,35–37] and in various normal cells [31,38,39].
Importantly, our investigation did not confirm a significant
presence of the inhibitory phosphorylation of CDK4 at the Y17
site (or CDK6 at Y25) [31,33], which corresponds to crucial Y15/
T14 phosphorylations of CDK2 and CDK1 [40,41].
This determining regulation of CDK4 T172 phosphorylation
contrasts with the prevalent concept that the activating phosphor-
ylations of the different CDKs, including CDK4 and CDK6, are
performed solely by the only CDK-activating kinase (CAK) known
in metazoan cells, which is composed of the cyclin H-CDK7-Mat1
complex [42–44]. This complex is constitutively active [31,45],
even when assayed on CDK4 [36,37,46]. Other puzzling
observations also raised doubts that CAK/CDK7 could be the
main (or the sole) CDK4-activating kinase (reviewed in [35]). For
instance, CDK4 phosphorylation can be differentially regulated in
cyclin D1 or cyclin D3 complexes [36,47]. Moreover, T172-
phosphorylated CDK4 is enriched in p27-bound cyclin D-CDK4
complexes [31], whereas p27 binding prevents CDK phosphor-
ylation by CAK/CDK7 [15,48]. Finally, the regulation of CDK4
phosphorylation does not apply to CDK6, which remains barely
phosphorylated inmany cells [31,33]. We ascribed this to the absence
of a conserved adjacent proline residue that is uniquely present in the
phosphoacceptor domain of CDK4 (QMALTPVVVT in CDK4 vs
QMALTSVVVT in CDK6) [30,33]. P173 mutations of CDK4
abrogated its T172 phosphorylation in cells, while S178P mutation of
CDK6 led to its complete T177 phosphorylation [33]. However,
CDK2 and CDK6 are much better in vitro substrates of CAK/CDK7
than CDK4 [31–33,49]. Moreover, P173S mutation of CDK4 did
not impair its in vitro activation by CAK [33], which is consistent with
the concept that CDK recognition by CAK does not depend on a
consensus sequence around the phosphoacceptor site [49–52].
We thus hypothesized that unlike CDK2 and CDK1 [53],
CDK4 is not activated in cells by cyclin H-CDK7, but by one or
several proline-directed kinase(s). The hypothesis that animal cells
have multiple CAKs like yeasts and plant cells [44,54] is not novel
[44,55,56] and it could help to resolve the complex issue of the
divergent constrains of the dual roles of CDK7 in cell cycle and
mRNA transcription [50]. Alternatively, CDK7 could still be the
catalytic subunit of the proline-directed CDK4-activating kinase
that we postulated. Indeed, cyclin H-CDK7-Mat1 associated with
TFIIH phosphorylates non-CDK substrates at T/S-P motifs [49].
RNAi-mediated (partial) depletion of CDK7 is generally
insufficient to affect cell cycle progression and thus CDK activity.
Moreover, approaches based on inhibition of CDKs or their
knockout (or knockdown) have generated divergent conclusions
[57]. As no specific inhibitor of CDK7 has been developed,
Robert Fisher’s group has replaced in HCT116 human colon
carcinoma cells the two CDK7 alleles by a mutated CDK7 (F91G)
that can be specifically inhibited by ‘‘bulky’’ adenine analogs
(K7AS HCT116 cells) [53]. These cells enabled us to (i)
demonstrate crucial –but unexpectedly complex and partly
indirect– involvements of CDK7 in CDK4 and CDK6 activation,
(ii) uncover novel positive feedback pathways mediated by p21
phosphorylation and involving CDK7-dependent activities of
CDK4 and CDK2 in CDK4 activation, and (iii) demonstrate
the existence of non-CDK7 CDK4-activating kinase(s).
Results
Acute requirement for CDK7 activity in CDK4 and CDK6
activation in HCT116 cells
Cell cycle progression and kinetics of CDK4 phosphorylation
upon stimulation of serum-deprived K7ASHCT116 cells with 10%
serum were analyzed as detailed in Figure S1 and its legend. The
relative presence of phosphorylated and non-phosphorylated
CDK4 forms in coimmunoprecipitated complexes was assessed
by 2D-gel electrophoresis as previously [31] (Figure S1C). We have
previously identified the most negatively charged form as
the T172-phosphorylated CDK4 using several approaches:
[32P]phosphate incorporation, a phospho(T172)-specific CDK4
antibody, in vitro phosphorylation by recombinant CAK, and
analysis of T172A-mutated CDK4 [31,33]. Here, the phosphory-
lation of cyclin D1-bound CDK4 appeared at 2–3 h into G1 phase,
whereas the phosphorylation of cyclin D3-bound CDK4 was
detectable in serum-deprived cells and increased much later at 12 h
and subsequent time points, when most cells were in S–G2 phases
(Figure S1C).
Author Summary
In the cell cycle, duplication of all the cellular components
and subsequent cell division are governed by a family of
protein kinases associated with cyclins (CDKs). Related CDK4
and CDK6 bound to cyclins D are the first CDKs to be
activated in response to cell proliferation signals. They thus
play a central role in the cell multiplication decision,
especially in most cancer cells in which CDK4 activity is
highly deregulated. We have identified the activating T172
phosphorylation instead of cyclin D expression as the highly
regulated step determining CDK4 activation. This finding
contrasts with the prevalent view that the only identified
metazoan CDK-activating kinase, CDK7, is constitutively
active. By using human cells genetically engineered for
specific chemical inhibition of CDK7, we found that CDK7
activity was indeed required for CDK4 activation. However,
this dependence was conditioned by CDK4 binding to the
CDK inhibitory protein p21, which increased in response to
CDK7 inhibition. Further investigation revealed that CDK7
inhibition affects a major phosphorylation of p21, which we
found to be required for CDK4 activation and performed by
CDK4 itself and CDK2. Thus, depending on CDK7 activity,
CDK4 and CDK2 facilitate CDK4 activation, generating novel
positive feedbacks involved in the cell cycle decision.
CDK7/CDK4/CDK2/p21 Interplay at R Point
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To test whether CDK7 inhibition affects the activation of CDK4
through T172-phosphorylation, serum-deprived wild-type (wt) and
K7ASHCT116 cells were re-stimulated by serum in the continuous
presence or absence of the bulky adenine analog 1-NMPP1 (10 mM)
to specifically inhibit CDK7 activity. As previously shown [53], 1-
NMPP1 prevented the induction of DNA synthesis in K7AS but not
in wt HCT116 cells (Figure 1A). This was associated with a similar
inhibition of the stimulated T826 phosphorylation of pRb in K7AS
but not in wt cells, without any inhibition of the accumulation of
cyclin D1, cyclin D3 or CDK4 (Figure 1B; Figure S2A). Instead,
cyclin D1 accumulation increased further at 8 and 16 h in response
to CDK7 inhibition in K7AS cells (Figure S2A), likely due to
impairment of the degradation it undergoes during S-phase
progression. Serum-stimulated T160 phosphorylation of CDK2
was also inhibited only in K7AS cells, as previously demonstrated
[53]. Interestingly, a marked accumulation of p21 in response to
CDK7 inhibition was observed at 8 h and even more at 16 h
(Figure 1B; Figure S2A).
In the same experiments, we analyzed in K7AS cells the effect of
CDK7 inhibition on the pRb-kinase activity of CDK4 and CDK6,
both of which were immunoprecipitated using antibodies against
cyclin D1, D3, p21 or CDK6. The protein composition of these
complexes was also analyzed by western blotting (Figure 1C; Figure
S2C). CDK7 inhibition by 1-NMPP1 largely or totally inhibited the
serum-stimulated activity of CDK4 and CDK6 without reducing
their association with cyclin D1 or cyclin D3. As generally observed
in unperturbed cell cycles [3,10,58], p21-bound CDK4/6 was
largely active in response to serum stimulation, and here again its
activity was inhibited by 1-NMPP1 treatment (Figure 1C).
The inhibition of pRb-kinase activity in response to selective
CDK7 inhibition was associated with reduced phosphorylations of
CDK4 and/or CDK6. Co-immunoprecipitation of these kinases
and separation of their phosphorylated forms by 2D-gel electro-
phoresis showed that continuous treatment with 1-NMPP1 during
serum stimulation abolished the phosphorylation of CDK4 bound
to cyclin D1, cyclin D3 or p21 in K7AS but not in wt HCT116
cells (Figure 1D). Consistent with our previous observations [33],
CDK6 was less phosphorylated than CDK4 and its T177-
phosphorylated form was detected in cyclin D1-CDK6 but not
in cyclin D3-CDK6. Phosphorylation of cyclin D1-bound CDK6
was also inhibited in response to CDK7 inhibition (Figure S2B).
Application of CDK7 inhibition after mitogenic stimulation has
been reported to have only a delayed effect on CDK2 activity
because T160 phosphorylation of CDK2 is stabilized by cyclin
binding [53]. We thus wanted to compare the stability of the
activating phosphorylations of CDK2 and CDK4, and of CDK4
activity, in response to shorter treatments with 1-NMPP1 in K7AS
cells. Serum-deprived K7AS cells were stimulated for 5 h before
treating them for 1 or 3 h with 1-NMPP1. Both the CDK4/6 pRb
kinase activity (Figure 2A) and CDK4 phosphorylation (Figure 2B)
completely disappeared after 1 h of CDK7 inhibition. By contrast,
T160 phosphorylation of CDK2 was only partially reduced 3 h
after 1-NMPP1 administration (Figure 2B).
These results show that the activation of CDK4 and CDK6 in
vivo depends critically on CDK7 activity. Moreover, CDK4
phosphorylation is labile and thus more prone to rapid regulation,
potentially making CDK4 the most influential target of CDK7 in
G1/S transition.
CDK4 complexes from CDK7-inhibited cells are more
strongly associated with p21 and are refractory to in vitro
activation by CAK
In co-immunoprecipitations using antibodies against cyclin D1
and cyclin D3, we noticed a marked increase in the association of
p21 in response to sustained CDK7 inhibition. This increase was
not paralleled by a similar increase of CDK4 and CDK6
associations (lanes 3 and 5 in Figure 1C). Interestingly, the
increased association of p21 was already observed at the 5 h time
point, when the total p21 level had not yet increased in response to
CDK7 inhibition (Figure 1B, 1C). Because in serum-stimulated
HCT116 cells in G1 (which express relatively higher p21 levels
than other cells) most of CDK4 and CDK6 complexes are
stabilized by p21 and hence contain it, the increased p21 binding
in response to CDK7 inhibition indicated an increased stoichi-
ometry (and/or stability) of p21 binding to cyclin D complexes.
Binding of more than one p21 molecule is known to preclude the
activity of cyclin D-CDK4-p21 complexes [3,6,10]. Therefore, we
designed experiments to evaluate the extent to which this
increased association of p21 could contribute to inhibition of the
activation of CDK4/6 caused by CDK7 inhibition.
We first evaluated if CDK4 and CDK6 complexes from CDK7-
inhibited cells can be re-activated by CAK. Indeed, if the impaired
activation of CDK4 and CDK6 complexes in CDK7-inhibited
K7AS cells was due only to the absence of activating phosphor-
ylation, these complexes should remain phosphorylatable by CAK.
We and others have shown that cyclin D3-CDK4 can be
phosphorylated and activated in vitro by cyclin H-CDK7-MAT1
(CAK) complexes [15,31,46]. Nevertheless, this is a relatively
inefficient process, which requires higher (millimolar) ATP
concentrations [31,33], compared with in vitro phosphorylation of
CDK2 and cyclin D3-CDK6 [32,42,49].
Cyclin D1 and cyclin D3 immunoprecipitates from K7AS cells
–which contained mostly unphosphorylated CDK4 and CDK6
after serum-deprivation or re-stimulation by serum in the presence
of 1-NMPP1– were incubated with 2 mM ATP and active
recombinant CAK. As shown in Figure S3 and detailed in its
legend, only cyclin D3-CDK6, but neither cyclin D3-CDK4,
cyclin D1-CDK4 nor cyclin D1-CDK6, could be phosphorylated
by CAK from 1-NMPP1-treated cells. However, as a positive
control in the same experiment, CAK efficiently phosphorylated
cyclin D3-CDK4 complexes that were produced in CHO cells
(and hence were not associated with p21 [33]) and were
dephosphorylated by l-phosphatase (Figure S3, inset). The
refractoriness to CAK activation of cyclin D3-CDK4 from
CDK7-inhibited cells (Figure S3) might have been due to its
increased association with p21 (Figure 1C). Indeed, p21-bound
CDK4 and CDK6 from CDK7-inhibited cells were also refractory
to phosphorylation by CAK (Figure S3).
CDK4 activation correlates with S130 phosphorylation of
p21, which is prevented by CDK7 inhibition
To better understand how p21 could intervene in the regulation
of CDK4 activation even before the increase of p21 steady-state
level, we evaluated p21 modifications in K7AS cells by 2D gel
electrophoresis. As shown in Figure 3A, one main more negatively
charged form appeared in response to serum stimulation in both
total p21 and p21 bound to cyclin D1 and cyclin D3 complexes.
More modified minor forms in stimulated cells were detected by
longer exposure of the western blots (Figure S4A). l-phosphatase
treatment showed that all the modified forms resulted from
phosphorylation (not shown). The main single phosphorylated p21
form was induced 2–3 h after serum stimulation, coinciding with
the appearance of the T172-phosphorylated form of CDK4
(Figure S4C). During the reduction of p21 levels associated with
late G1 and S-phase progression, this phosphorylated form
became the most abundant one. Later (16–20 h), coinciding with
cyclin A expression (Figure S1B), the minor multi-phosphorylated
forms of p21 became more abundant (Figure S4C). Importantly,
CDK7/CDK4/CDK2/p21 Interplay at R Point
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Figure 1. Specific inhibition of CDK7 by 1-NMPP1. Specific inhibition of CDK7 by 1-NMPP1 prevents DNA synthesis (A), pRb phosphorylation
(B), CDK4/6 pRb-kinase activity (C) and CDK4 activating phosphorylation (D). HCT116 WT or K7AS (K7as/as) cells were stimulated (+) or not stimulated
(2) with FBS for the indicated times in the absence (2) or presence (+) of 1-NMPP1. (A) DNA synthesis was evaluated from duplicate dishes by
counting the percentage of cells having incorporated BrdU during the last 30 min of stimulation. (B) Western blotting analysis with the indicated
CDK7/CDK4/CDK2/p21 Interplay at R Point
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inhibition of CDK7 by 1-NMPP1 prevented the appearance of the
main and minor (multi) phosphorylated forms of p21 (Figure 3A;
Figure S4A). As observed for CDK4 phosphorylation (Figure 2B),
the phosphorylated forms of p21 already disappeared 1 h after 1-
NMPP1 administration (Figure S4B).
We next wanted to identify the phosphorylation sites of p21 in
K7AS cells. Different phosphorylated forms of a protein present
characteristic reproducible migrations in 2D gel separations,
which allows them to be monitored once they are identified
[41]. As the phosphorylations of p21 depended on CDK7 activity,
we hypothesize that they could have been catalyzed by CDKs,
which phosphorylate S/T-P motifs. p21 contains three such motifs
(T57, S98, S130). So we produced human p21 and its T57A, S98A
and S130A mutants in CHO cells, and compared their 2D gel
separation patterns after in vitro phosphorylation by active
recombinant CDK complexes. In the same experiments, p21
was also produced as a complex with cyclin D3 and CDK4
(immunoprecipitated by the DCS-28 cyclin D3 antibody) to
evaluate how the accessibility of p21 phosphorylation sites might
have been affected. As analyzed in Figure 3B and Figure S5, cyclin
E1-CDK2 and cyclin D3-CDK4 phosphorylated unbound p21 at
both S130 and S98 but not at T57 (the patterns were not affected
by the T57A mutation), whereas only S130 was phosphorylated by
cyclin A2-CDK2. In p21 complexed with cyclin D3 and CDK4,
phosphorylation of S130 by cyclin E1-CDK2 and cyclin D3-
CDK4 was more complete, while S98 phosphorylation was much
reduced. By contrast, after incubation with cyclin A2-CDK2,
cyclin D3/CDK4-bound p21 was more completely phosphorylat-
ed and several multi-phosphorylated forms appeared. The S130A
mutation affected all the phosphorylated forms (Figure S5B). The
multi-phosphorylated forms were similarly affected by the S98A
mutation, whereas the T57A mutation had no effect (Figure S5B).
Therefore, after phosphorylation by cyclin A2-CDK2, all phos-
phorylated forms of cyclin D3/CDK4-bound p21 contained the
S130 phosphorylation, and its most abundant forms resulted from
a combination of S130 and S98 phosphorylations associated with
one or two unidentified phosphorylations (but not on T57)
(Figure 3B; Figure S5). In similar in vitro experiments, the
association of p21 with cyclin D1-CDK4 was also required for
its complete S130 phosphorylation by cyclin D1-CDK4 and cyclin
D1-CDK6 (Figure S6). Overall, these observations suggest that
interaction of p21 with cyclin D-CDK4 increases the accessibility
of the S130 residue to the five recombinant active CDKs we
tested, and the accessibility of S98 to cyclin A2-CDK2 only, while
impairing S98 accessibility to cyclin E1-CDK2 and cyclin D1/D3-
CDK4. CDK4 was not phosphorylated by recombinant CDK2
and CDK4 complexes in these experiments (not shown).
Comparison of in vitro and in vivo phosphorylation patterns of
p21 (Figure 3C) showed identical migration of forms generated by
cyclin E1-CDK2 and cyclin D1/D3-CDK4/6 with those that
appeared in K7AS cells at time points corresponding to G1 and
early S-phase progression (see also Figure S4C). This indicates that
p21 was mostly phosphorylated at S130 and S98 (the single S130-
phosphorylated form being the most abundant one). Additional
multi-phosphorylated p21 forms that appeared during late S and
the G2 phase comigrated identically with those generated by
phosphorylation of cyclin D3/CDK4-bound p21 by cyclin A2-
CDK2 (Figure 3C). As also confirmed by p21 mutation in intact
cells (see below), the phosphorylation of p21 induced by mitogenic
stimulation and inhibited by CDK7 inhibition occurred mainly at
residue S130.
antibodies from whole-cell lysates. (C) Cell lysates were immunoprecipitated (IP) with anti-cyclin D1 (D1), anti-cyclin D3 (D3) or anti-p21 (p21)
antibodies and were assayed for their pRb-kinase activity, separated by SDS-PAGE and immunoblotted with the indicated antibodies (C). (D) The
same immunoprecipitates were separated by 2D gel electrophoresis followed by immunodetection using antibodies directed against CDK4 or T172-
phosphorylated CDK4. Arrows, T172-phosphorylated form of CDK4.
doi:10.1371/journal.pgen.1003546.g001
Figure 2. Effect of acute inhibition of CDK7 by 1-NMPP1. Effect
of acute inhibition of CDK7 by 1-NMPP1 on CDK4 activity (A) and
phosphorylation (B). (A,B) HCT116 K7AS cells were stimulated with FBS
for 5 h and 1-NMPP1 was then added for 1 or 3 h. Cell lysates were
immunoprecipitated (IP) with anti-cyclin D1 (D1), or anti-p21 antibodies,
assayed for their pRb-kinase activity, separated by SDS-PAGE and
immunoblotted with the indicated antibodies (A), or separated by 2D
gel electrophoresis followed by CDK4 immunodetection (B). In (B), T160
phosphorylation of CDK2 immunodetected from whole cell extracts is
shown for comparison.
doi:10.1371/journal.pgen.1003546.g002
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Figure 3. Specific inhibition of CDK7 by 1-NMPP1 prevents the main phosphorylation of p21, which is performed in vitro by both
CDK4 and CDK2. (A) HCT116 K7AS cells were stimulated (+) or not stimulated (2) with fetal bovine serum (FBS) for the indicated times in the
absence (2) or presence (+) of 1-NMPP1. Cell lysates were immunoprecipitated (IP) with anti-p21, anti-cyclin D1 (D1) or anti-cyclin D3 (D3) antibodies
and separated by 2D gel electrophoresis followed by p21 immunodetection. (B) CHO cells were transfected with a p21-expressing plasmid alone (left)
or with plasmids encoding cyclin D3, CDK4-HA and p21 (right). Cell lysates were immunoprecipitated (IP) with anti-p21 (p21) or anti-cyclin D3 (D3)
antibodies and incubated with the indicated recombinant kinases and ATP, before separation by 2D gel electrophoresis and p21 immunodetection.
Arrows indicate the main phosphorylated forms of p21 as identified in Figure S4. (C) Schematic representation and comparison of p21 patterns from
HCT116 K7AS cells that were restimulated for 3 and 20 h (in vivo) and from cyclin D3-CDK4-p21 complexes produced in CHO cells and
phosphorylated by recombinant CDK2-cyclin E and CDK2-cyclin A (in vitro). The observed p21 forms are labeled according to their number of
phosphorylations and the identified phosphorylated residues (e.g., 2P 98,130 means p21 phosphorylated at both S98 and S130; X, Y, unidentified
phosphorylated sites).
doi:10.1371/journal.pgen.1003546.g003
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Figure 4. Reciprocal impacts of p21 and cyclin D3-CDK4 on T172 phosphorylation of CDK4 and S130 phosphorylation of p21 in
transfected CHO cells. (A) p21 stabilizes cyclin D3-CDK4 complexes and inhibits their activity depending on its expression level. CHO cells were
transfected with plasmids encoding cyclin D3 and CDK4-HA with or without p21 at high (p21) or low (p21 1/10) expression level. Cell lysates (WCE)
were immunoprecipitated (IP) with anti-cyclin D3 (D3) or anti-p21 antibodies, assayed for their pRb-kinase activity, separated by SDS-PAGE and
immunoblotted with the indicated antibodies. (B) p21 expressed alone is essentially unphosphorylated. CHO cells were transfected with a plasmid
encoding p21 at high (p21) or low (p21 1/10) expression level. Cell lysates were immunoprecipitated (IP) with anti-p21 antibody and separated by 2D
gel electrophoresis followed by p21 immunodetection. (C) Co-expression of cyclin D3-CDK4 induces the phosphorylation of p21, largely
independently of CDK4 activity, whereas stronger expression of p21 inhibits phosphorylations of both p21 and CDK4. CHO cells were transfected with
plasmids encoding cyclin D3 and CDK4-HA or its inactive mutants (T172A, K35R) with or without p21 at high (p21) or low (p21 1/10) expression level.
Cell lysates were immunoprecipitated (IP) with anti-cyclin D3 antibody and separated by 2D gel electrophoresis followed by CDK4 and p21
immunodetection. (D) Identification of p21 phosphorylation sites. CHO cells were transfected with plasmids encoding cyclin D3, CDK4-HA and wild
type (WT) or mutated (S130A, S98A) p21 at low (p21 1/10) expression level. Cell lysates were immunoprecipitated (IP) with anti-cyclin D3 antibody
and separated by 2D gel electrophoresis followed by p21 immunodetection. Black arrows, T172-phosphorylated CDK4. Colored arrows indicate
phosphorylated forms of p21.
doi:10.1371/journal.pgen.1003546.g004
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To further evaluate the relationship between p21 and CDK4
T172 phosphorylation in intact cells, p21 was co-expressed at two
different levels with cyclin D3 and CDK4 by transfection of CHO
cells (in which no endogenous p21 is detectable) (Figure 4). The
effect of p21 expression on the assembly and activity of CDK4
complexes was exactly as established [10,58–60]. In the absence of
p21, very active cyclin D3-CDK4 complexes were formed [31],
and they were largely phosphorylated at T172 (Figure 4A, 4C). At
the higher level of expression, p21 stabilized cyclin D3-CDK4
complexes but inhibited their pRb-kinase activity (Figure 4A) and
also substantially reduced CDK4 phosphorylation (Figure 4C). By
contrast, at the lower expression level of p21, p21-bound cyclin
D3-CDK4 complexes displayed a weak but readily detected
activity (Figure 4B) and a much increased phosphorylation of
CDK4 (Figure 4C).
When expressed alone, whether at a high or a low level, p21 was
essentially unphosphorylated (Figure 4B). Intriguingly, in the ‘‘low
p21’’ setting, the co-expression of cyclin D3-CDK4 induced the
phosphorylation of p21 at S130 and less abundantly at S98 (as
shown by comparison with S130A and S98A mutants) (Figure 4C,
4D). This effect of cyclin D3-CDK4 on S130 phosphorylation
mostly did not depend on the activity of the CDK4 complex, as
observed by comparison with two inactive CDK4 mutants, T172A
and K35R (Figure 4C). On the other hand, in the ‘‘high p21’’
setting, p21 and CDK4 were essentially unphosphorylated
(Figure 4C), and the relative presence of p21 was also increased
in the CDK4 complex (Figure 4A, compared to the ‘‘low p21’’
setting in the cyclin D3 immunoprecipitation).
All together, experiments on transfected CHO cells further
established the correlation between T172 phosphorylation of
CDK4 and S130 phosphorylation of p21. Binding of p21 to cyclin
D3-CDK4 might expose S130 to another kinase, as also suggested
by the previous in vitro experiments. That this p21 S130-kinase
could itself be inhibited by p21 is suggested by the observation that
S130 phosphorylation of p21 was not induced in cyclin D3-CDK4
complexes when p21 was expressed at concentrations that largely
exceed the binding capacity of the CDK4 complex.
Previous reports have indicated that S130 phosphorylation of
p21 can be catalyzed by CDK2 to form a phosphodegron
recognized by the SCF/Skp2 ubiquitin ligase complex and to
signal the proteasomal degradation of cyclin/CDK-bound p21,
which is required for S-phase entry [61–63]. To evaluate whether
inhibition of proteasomal degradation of p21 could indeed affect
CDK4 phosphorylation, K7AS HCT116 cells were stimulated by
serum in the presence or absence of the proteasome inhibitor
MG132 (Figure S7). MG132 increased p21 levels (Figure S7A) and
strongly inhibited the pRb-kinase activity associated with cyclin
D1 and p21 (Figure S7B). Here also, both the T172 phosphor-
ylation of CDK4 and the S130 phosphorylation of p21 were
inhibited by MG132 (Figure S7C).
S130 phosphorylation of p21 is instrumental in CDK4
activation
To evaluate the effect of the S130 phosphorylation of p21 on
the activation of CDK4 in HCT116 cells, we generated by
lentiviral infection TetON-inducible K7AS cells that inducibly
express 36HA-tagged wt or S130A p21. 36HA-p21 was induced
by doxycycline and the cells were stimulated by serum. Upon
induction by doxycycline, ectopic p21 expression from puromy-
cine-selected cells was maintained well below the level of
endogenous p21 and it was identical in wt and S130A 36HA-
p21 cells (Figure 5A). From these cells, ectopic p21 was
immunoprecipitated with an HA antibody and the immunopre-
cipitates were separated by 2D-gel electrophoresis to analyze the
phosphorylations of 36HA-p21 and CDK4 bound to the ectopic
p21 (co-detected using a mixture of p21 and CDK4 antibodies). As
shown in Figure 5B, in serum-stimulated cells the main singly
phosphorylated form of p21 was abrogated by the S130A
mutation, confirming its identification. Moreover, CDK4 phos-
phorylation was much reduced by the S130A p21 mutation
(Figure 5B). Therefore, inhibition of S130 phosphorylation of p21
could really contribute to impairment of CDK4 activation.
Additional experiments were performed to understand how
S130 phosphorylation could affect the activation of p21-bound
cyclin D-CDK4 complexes (detailed in Figure S8 and its legend).
Since the increased association of p21 to CDK4 complexes in
response to CDK7 inhibition occurred before the increased
accumulation of overall p21 (Figure 1B, 1C), we envisaged an
effect of the S130 phosphorylation on the stability of the
interaction of p21 with CDK4 complexes. p21 interacts with
cyclin-CDK complexes through two cyclin-binding sites, desig-
nated Cy1 and Cy2, respectively located in the N and the C
terminus, and a single CDK-binding site (K) closer to the central
region [64]. Inducible expression of the S130D ‘‘phosphomimetic’’
36HA-p21 mutant in K7AS HCT116 cells did not reproducibly
affect the binding of p21 to CDK4 complexes or CDK4
phosphorylation (Figure S8A). However, in the presence of
another p21 mutation that affects the K CDK-binding site
(T57D; [65] and our unpublished data), the S130D mutation
markedly reduced the co-immunoprecipitation of CDK4 with
36HA-p21 (Figure S8A). Interestingly, CDK4 complexed with the
double T57D/S130D p21 mutant was also more abundantly
phosphorylated than CDK4 bound to T57D p21 (Figure S8A).
Finally, as shown in Figure S8B and detailed in its legend, we also
tested the effect of in vitro phosphorylation of p21 by CDK2 on the
subsequent phosphorylation of the p21-bound CDK4 by CAK. In
the T57D mutation context, in vitro phosphorylation by cyclin A2-
CDK2 reduced p21 interaction with CDK4, thereby allowing
complete phosphorylation by CAK of the remaining p21-bound
CDK4 (Figure S8B).
All together, these experiments demonstrate that S130 phos-
phorylation of p21 is required for phosphorylation of p21-bound
CDK4. Moreover, they suggest that S130 phosphorylation might
modify the interaction of p21 with cyclin D-CDK4 to increase the
accessibility of CDK4 T172 to CAK (and possibly to other
kinases).
CDK2 and CDK4/6 activities are both required for S130
phosphorylation of p21 and CDK4 activation
In vitro, p21 bound to cyclin D-CDK4 was efficiently
phosphorylated at S130 by cyclin E- CDK2 and cyclin A-CDK2
complexes, and in transfected CHO cells S130 was phosphory-
lated by p21-inhibitable kinase(s). To ascertain the possible
involvement of CDK2 in S130 phosphorylation of p21 and hence
in CDK4 activation, we first stimulated K7AS HCT116 cells in
the presence or absence of the specific CDK inhibitor roscovitine,
which in vitro inhibits several CDKs but not CDK4 and CDK6
[66]. Using a concentration of R-roscovitine (20 mM) that has little
effect on cell cycle and survival in CDK2-null MEFs [66], we
observed a strong inhibition of pRb phosphorylation, including at
the T826 CDK4/6-specific site. The effect was already observed
in G1 phase (5 h after stimulation), and at that time it was not
associated with any major changes in the expression of p21
(Figure 6A; noteworthy, p21 was strongly induced by roscovitine
at later time points). Here again, the T172 phosphorylation of
CDK4 as well as S130 phosphorylation of p21 were inhibited by
roscovitine (Figure 6B). Nevertheless, T160 phosphorylation of
CDK2 was also reduced (Figure 6A), suggesting that roscovitine
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might have inhibited CDK7 in addition to CDK2, as reported
previously [67].
Therefore, we also used S-CR8 (0.5 mM), a more potent and
selective derivative of roscovitine, with a 20-fold lower in vitro IC50
for inhibition of CDK2 than CDK7 [68]. Analysis of the
phosphorylations of the C-terminal domain (CTD) of the large
subunit of RNA polymerase II indeed confirmed that CR8 likely
inhibited CDK9 in addition to CDK2, but unlike roscovitine, not
CDK7 (Figure S9A and its legend). In the same experiments, CR8
inhibited the serum-stimulated phosphorylation of p21 and CDK4
(Figure 6C), further supporting the involvement of CDK2.
We then compared the short term effect on CDK4 activation of
roscovitine, CDK7 inhibition by 1-NMPP1, and CDK2 inhibition
by CR8. Whereas continuous treatment with CR8 abolished
CDK4 activation (Figure 6C), CDK7 inhibition and roscovitine
inhibited CDK4 activity (not shown) and phosphorylation in 1 h,
but CR8 did not (Figure S9B). Therefore, the effect of CDK2
inhibition was delayed compared to the abrupt arrest of CDK4
activation resulting from CDK7 inhibition, suggesting that CDK7
inhibition can affect CDK4 activation by both indirect (CDK2-
mediated) and more rapid (CDK2-independent) mechanisms. This
result also confirmed that CR8 did not affect CDK4 activation by
inhibiting CDK7.
Finally, we wanted to exclude the possibility that CDK2
inhibition by CR8 can indirectly affect CDK7 activity. Based on in
vitro experiments, CDK2 was indeed proposed to be responsible
for T170 phosphorylation of CDK7 [51]. As shown in Figure
S10A, the capacity of cyclin H-CDK7 complexes of HCT116
K7AS cells to activate cyclin D3-CDK4 in vitro was affected only
slightly by stimulating these cells with serum (confirming previous
reports from other cell systems [36,37,46]) or inhibiting CDK2 by
CR8. In K7AS cells, the association of CDK7 and XPD [69] with
cyclin H was not modified by these treatments, although MAT1
association was slightly increased by serum stimulation (Figure
S10A). Furthermore, by combining 2D electrophoresis and a
phosphospecific T170 CDK7 antibody, we found that almost all
cyclin H-bound CDK7 was phosphorylated at T170 as well as at a
second site, likely S164 [51]. This CDK7 phosphorylation profile
was not affected in cells continuously treated with CR8 (Figure
S10B). Therefore, the proposed mechanisms of CDK7 regulation
[50] cannot explain the regulation of CDK4 T-loop phosphory-
lation and the effect of CR8 in our experiments.
We observed that CDK4 and CDK6, associated with cyclin D3
and cyclin D1, also phosphorylated p21 complexed with D-type
cyclins and CDK4 in vitro (Figure 3B; Figure S6). So we evaluated
the effect of PD0332991 on S130 phosphorylation and CDK4
activation in K7AS HCT116 cells (Figure 7). PD0332991 is a
specific inhibitor of CDK4 and CDK6 and does not inhibit CDK2
and the proliferation of pRb-negative cells [27,70]. PD0332991
(250 nM) inhibited the T826 phosphorylation of pRb (not shown)
and partially the S130 phosphorylation of p21, but apparently not
the S98 phosphorylation (Figure 7B). Treatment of the cells with
PD0332991 did inhibit the phosphorylation and consequently in
vitro activity of p21-bound CDK4 (Figure 7A, 7B). This indicates
that this drug inhibited not only the activity of CDK4 but also its
activation by phosphorylation, which might be related to the
Figure 5. S130 phosphorylation of p21 is instrumental in CDK4 activation. (A,B) Stably infected HCT116 K7AS cells for Tet-On inducible
36HA-p21 wt or S130A mutant were treated with doxycycline (1 mg/ml) for 16 h prior cell restimulation with fetal bovine serum (FBS) for 16 h in the
continuous presence of doxycycline. (A) Immunodetection of 36HA-p21 and endogenous p21 from whole cell extracts (WCE) using a p21 antibody.
(B) Cell lysates were immunoprecipitated (IP) with anti-HA antibody and separated by 2D gel electrophoresis followed by simultaneous
immunodetection of ectopic 36HA-p21 and 36HA-p21-bound endogenous CDK4 using a mixture of anti-CDK4 and p21 antibodies. Black arrows,
T172-phosphorylated CDK4. Colored arrows indicate phosphorylated forms of p21.
doi:10.1371/journal.pgen.1003546.g005
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inhibition of p21 phosphorylation. Curiously, and at variance with
all the inhibitory treatments we used, such inhibitory effects of
PD0332991 cell treatment on CDK4 activation were not observed
for CDK4 precipitated by antibodies against cyclin D1 (Figure 7A,
7B) and cyclin D3 (not shown). This puzzling and very
reproducible discrepancy necessarily implies that in PD0332991-
treated cells the active phosphorylated cyclin D1/3-bound CDK4
was no longer associated with p21. We speculate that high-affinity
binding of this ATP-competing drug to CDK4 in cells had
somehow impaired p21 binding to CDK4, e.g. by competing with
the insertion of the 310 helix of p21 in the catalytic cleft of CDK4
or by altering the folding of CDK4. Regardless of the reason, these
observations show that the effect of PD0332991 on CDK4
activation depended on the binding of CDK4 to p21. They thus
suggest that CDK4 (and/or CDK6) might contribute to the
activation of p21-bound CDK4 complexes by phosphorylating
p21.
In asynchronously proliferating CHO cells transfected to
overexpress cyclin D3 and CDK4 in the presence of a limiting
amount of ectopic p21 (performed as in Figure 4), roscovitine
Figure 6. Inhibition of phosphorylations of p21 and CDK4 by CDK inhibitors. HCT116 K7AS cells were stimulated (+) or not stimulated (2)
with fetal bovine serum (FBS) for the indicated times in the absence (2) or presence (+) of roscovitine (rosco) (A,B) or CR8 (C). (A) Western blotting
analysis with the indicated antibodies from whole-cell lysates. (B,C) Cell lysates were immunoprecipitated (IP) with anti-cyclin D1 (D1), anti-cyclin D3
(D3) or anti-p21 antibodies and separated by 2D gel electrophoresis followed by immunodetection of CDK4 and p21. Black arrows, T172-
phosphorylated CDK4; green arrows, S130-phosphorylated p21.
doi:10.1371/journal.pgen.1003546.g006
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treatment was insufficient to reduce the phosphorylations of
CDK4 and p21. This intriguing observation is at variance with the
situation observed in re-stimulated K7AS cells. So we re-
investigated the effect of roscovitine in the presence of CDK4/6
inhibition by PD0332991 in such transfected CHO cells
(Figure 7C). Whereas PD0332991 partly inhibited p21 phosphor-
ylation, roscovitine alone was inactive. Only the combination of
both inhibitors abrogated both p21 and CDK4 phosphorylations
Figure 7. Activities of both CDK4/6 and CDK2 are required for S130 phosphorylation of p21 and activation of p21-bound CDK4.
(A,B) HCT116 K7AS cells were stimulated (+) or not stimulated (2) with fetal bovine serum (FBS) for 5 h in the absence (2) or presence (+) of the
CDK4/6 inhibitor PD0332991. Cell lysates were immunoprecipitated (IP) with anti-cyclin D1 (D1) or anti-p21 antibodies, assayed for their pRb-kinase
activity, separated by SDS-PAGE and immunoblotted with the indicated antibodies (A), or separated by 2D gel electrophoresis followed by CDK4 and
p21 immunodetection (B). (C) CHO cells were transfected with plasmids encoding cyclin D3, CDK4-HA and p21 at low (p21 1/10) expression level (see
Figure 4), in the absence (DMSO as vehicle) or presence of CDK inhibitors: roscovitine (rosco), PD0332991 (1 mM) or their combination to inhibit both
CDK2 and CDK4. Cell lysates were immunoprecipitated (IP) with anti-cyclin D3 (D3) antibody and separated by 2D gel electrophoresis followed by
CDK4 and p21 immunodetection. Black arrows, T172-phosphorylated CDK4; colored arrows, phosphorylated forms of p21.
doi:10.1371/journal.pgen.1003546.g007
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(Figure 7C), suggesting that they depended on both CDK4/6 and
CDK2 (and/or CDK7) activities in this experimental setting.
It has been reported that to phosphorylate p21 on S130, cyclin
E-CDK2 has to interact with the C-terminus Cy2 cyclin-binding
motif of p21 [61]. To evaluate the importance of this motif in vivo,
we again used the lentiviral Tet-ON inducible system to express a
36HA-tagged deletion mutant of p21 lacking the Cy2 motif (aa 1
to 154; DCy2) in HCT116 cells. As performed in the previous
Figure 5 experiment, this mutant and wt p21 were induced by
doxycycline and the cells were stimulated by serum. Ectopic p21
was immunoprecipitated with an HA antibody and the immuno-
precipitates were separated by 2D-gel electrophoresis to analyze
the phosphorylations of 36HA-p21 and CDK4 bound to the
ectopic p21 (co-detected using a mixture of p21 and CDK4
antibodies). As shown in Figure S11, the DCy2 p21 mutant was
much less phosphorylated in response to serum stimulation than
wt p21. Moreover, serum did not increase the phosphorylation of
CDK4 bound to the DCy2 p21 mutant (Figure S11), as observed
with the S130A p21 mutant (Figure 5). Together with the previous
report [61], this result suggests that activation of p21-bound
CDK4 in vivo requires S130 phosphorylation of p21 by cyclin-
CDK complexes, which depends on their binding to the Cy2 site
of p21.
The requirement for CDK7 activity is dependent on CDK4
binding to p21, demonstrating the existence of CDK4-
activating kinase(s) other than CDK7 in HCT116 cells
We next wanted to verify the effect of CDK7 inhibition under
the experimental conditions that permitted us to propose the
existence of non-CDK7 proline-directed CDK4-activating kinases,
i.e. using ectopic cyclin D3-CDK4 overexpressed by cell
transfection as previously [33]. HCT116 K7AS cells were co-
transfected using expression plasmids encoding cyclin D3 and HA-
tagged CDK4 in the continuous presence or absence of 1-NMPP1.
The HA-tag allowed us to distinguish endogenous and ectopic
CDK4 after 2D gel separation from the same co-immunoprecip-
itations. As shown in Figure 8A, cyclin D3-bound CDK4-HA was
more phosphorylated than endogenous CDK4, and unlike
endogenous CDK4, its phosphorylation was largely resistant to
CDK7 inhibition. However, in the minor fraction of CDK4-HA
that could be co-immunoprecipitated through its binding to
endogenous p21 (using a p21 antibody), we observed a partial but
marked reduction of CDK4 phosphorylation after CDK7
inhibition by 1-NMPP1 (Figure 8A). Therefore, we reasoned that
the higher T172 phosphorylation level and its resistance to CDK7
inhibition seen in most ectopic cyclin D3-CDK4 complexes might
have been due to their overexpression, which allows them to
assemble without being stabilized by the endogenous p21, which
was not present in sufficient amounts.
We evaluated this possibility in a setting that did not depend on
CDK overexpression. We have previously shown that the
‘‘CDK4-mimicking’’ S178P mutation of CDK6 dramatically
increases its activity by inducing its almost complete T177
phosphorylation. Interestingly, phosphorylation of S178P CDK6
does not require cyclin binding (at variance with CDK4) [33], and
so it is not influenced by binding to a Cip/Kip protein, which
requires prior association with a cyclin [71]. By lentiviral infection,
we generated TetON-inducible K7AS cells that express Flag-
tagged wt or S178P CDK6, with or without cyclin D3, in response
to doxycycline (Figure 8B). In sharp contrast with wt Flag-CDK6,
the induced Flag-S178P CDK6 was almost completely T177-
phosphorylated, as shown by its previously characterized [33] 2D
gel separation (Figure 8B). The continuous presence of up to
30 mM of 1-NMPP1 to completely inhibit CDK7 activity during
the induction by doxycycline only minimally affected the
phosphorylation of S178P CDK6 expressed alone (without cyclin
D3) (Figure 8B). By contrast, when S178P CDK6 was co-induced
with cyclin D3 to allow its interaction with endogenous p21,
inhibition of CDK6 phosphorylation was much more pronounced
in the fraction of S178P CDK6 co-immunoprecipitated by the p21
antibody from CDK7-inhibited cells (Figure 8B), exactly as
observed for p21-bound ectopic CDK4-HA (Figure 8A).
To definitively establish the involvement of p21-binding in the
requirement for CDK7 activity in the activation of endogenous
CDK4, we compared the effect of the inhibition of both CDK2
and CDK7 by roscovitine in p21-null HCT116 cells and wt
HCT116 cells. As p21-null HCT116 cells did not survive serum
deprivation, both wt and p21-null cells were treated for 16 h with
roscovitine when cycling asynchronously (Figure 8C). Phosphor-
ylation of CDK4 bound to cyclin D1 or cyclin D3 was much more
abundant in p21-null cells (Figure 8C) (as observed for overex-
pressed cyclin D3-CDK4 in Figure 8A). Importantly, T172
phosphorylation of CDK4 was completely inhibited by roscovitine
in wt cells but not in p21-null cells (Figure 8C).
Collectively, our results indicate that in HCT116 cells the
crucial requirement for CDK7 activity in activating CDK4 by
phosphorylation is dependent on its binding to p21. On the other
hand, kinases other than CDK7 should exist to phosphorylate
p21-unbound CDK4 and S178P CDK6 during continuous CDK7
inhibition.
Discussion
In this study, specific inhibition of CDK7 in the human
HCT116 cell line led to several novel observations that collectively
reveal that the pRb-E2F switch at the R point is controlled by a
complex CDK7-dependent module involving bidirectional func-
tional interactions between CDK4 and CDK2. This process
targets the central T172 phosphorylation of CDK4 and is
mediated at least partly by S130 phosphorylation of p21. The
model depicted in Figure 9 assembles our main observations:
(i) CDK7 is required for CDK4 activation in vivo, but this
requirement is conditioned by CDK4 binding to p21, and
other CDK4-activating kinases must exist to phosphorylate
p21-unbound CDK4 during CDK7 inhibition.
(ii) The action of CDK7 on CDK4 activation is two-pronged.
In addition to having an initial acute effect on T172
phosphorylation of CDK4, CDK7 inhibition induced an
increased association of p21 to cyclin D-CDK4 complexes,
which might have been caused by reduction of the main
phosphorylation of p21 at S130. As shown by the
impairment of CDK4 phosphorylation by the S130A
mutation of p21, the inhibition of S130 phosphorylation
likely explains in part the inhibition of the activation of p21-
bound CDK4 complexes and the refractoriness of cyclin
D3-CDK4 complexes from CDK7-inhibited cells to in vitro
activation by CAK/CDK7. As reported by others [61,62],
the inhibition of S130 phosphorylation should also explain
the subsequent augmentation of overall p21 levels.
(iii) In vitro, S130 phosphorylation of p21 was performed not
only by cyclin E/A-CDK2 complexes, but also by CDK4
and CDK6 associated with cyclin D1 and cyclin D3. In vivo,
both S130 phosphorylation of p21 and T172 phosphoryla-
tion of p21-bound CDK4 were inhibited not only in
response to CDK7 inhibition, but also in response to
increased p21 expression and inhibition of CDK2 (by
roscovitine and CR8) and CDK4/6 (by PD0332991).
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Figure 8. CDK7 inhibition does not prevent activating phosphorylations of p21-unbound CDK4 and S178P CDK6. (A) HCT116 K7AS
cells were transfected with plasmids encoding cyclin D3 and CDK4-HA in the absence or continuous presence of 1-NMPP1 for 48 h. Cell lysates were
immunoprecipitated (IP) with anti-cyclin D3 or anti-p21 antibodies and separated by 2D gel electrophoresis followed by immunoblotting with anti-
CDK4 antibody, which detected both ectopic and endogenous CDK4. (B) HCT116 K7AS cells were infected during 24 h by lentiviruses encoding Tet-
On inducible wt or S178P CDK6-Flag with or without lentiviruses encoding Tet-On inducible cyclin D3. The expression of these proteins in the
continuous presence (+) or absence (2) of 1-NMPP1 was induced by doxycycline 16 h prior to cell restimulation by fetal bovine serum (FBS) for 16 h.
Western blotting detection of endogenous and ectopic (arrow) CDK6 from whole cell extracts is shown in the upper panel (NI, not infected). Cell
lysates were immunoprecipitated (IP) with anti-Flag, anti-cyclin D3 or anti-p21 antibodies and separated by 2D gel electrophoresis followed by
immunoblotting with anti-CDK6 antibody, which detected both ectopic and endogenous (e) CDK6. (C) T172 phosphorylation of endogenous CDK4
resists inhibition of CDK2 and CDK7 by roscovitine in p21-null (p212/2) cells. Roscovitine (rosco; +) or vehicle (2) were administered for 16 h to
asynchronously growing wild-type (WT) and p212/2 HCT116 cells cultured in parallel. Cell lysates were immunoprecipitated (IP) with anti-cyclin D1
(D1) or anti-cyclin D3 (D3) antibodies and separated by 2D gel electrophoresis followed by CDK4 immunodetection. Arrows, phosphorylated forms of
CDK4 and CDK6-Flag; arrowheads in (B), unphosphorylated form of CDK6-Flag.
doi:10.1371/journal.pgen.1003546.g008
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Inhibition of CDK4 phosphorylation by roscovitine and
PD0332991 depended on p21.
CDK7 involvement in CDK4 activation
Together with a parallel study by Fisher lab [72], our data
extend to CDK4 and CDK6 the concept that CDK7 activity is
critically required for the activating phosphorylation of all the
CDKs that orchestrate cell cycle progression [53,73,74]. As also
found in the parallel study [72], CDK4 complexes are much more
rapidly deactivated than CDK2 complexes in response to CDK7
inhibition, showing that the T172 phosphorylation of CDK4 is
exceptionally labile and thus potentially regulated by phosphatas-
es. Indeed, for CDK4, unlike CDK2, cyclin binding does not block
the accessibility of the phosphorylated T-loop to phosphatases
[33,75]. Because of this unique responsiveness of T172 phosphor-
ylation and its initializing role at R point, CDK4 might well be the
physiologically most significant target of CDK7 in G1/S
transition. On the other hand, in HCT116 K7AS cells and other
human cell lines including T98G cells, T-loop (T170) phosphor-
ylation of CDK7 and its activity on CDK4 [35–37] were
essentially constitutive (Figure S10 and unpublished results).
Perhaps due to slight differences in the used cells and/or
methodology, we were thus unable to confirm an important
stimulation by serum of CDK7 T170 phosphorylation [72].
How could the rapid responsiveness of CDK4 activation to
CDK7 inhibition be reconciled with the observations that raised
doubts about CAK being the sole CDK4 activating kinase (as
summarized in the Introduction; [35])? First, the unaffected
phosphorylation of ectopic cyclin D3-CDK4 and S178P CDK6
during CDK7 inhibition, as well as the unaltered phosphorylation
of endogenous p21-free CDK4 complexes, demonstrate that
CDK7 cannot be the sole CDK4-activating kinase as previously
postulated [33,35]. While completing our study, it was reported
that inactivation of Rb family proteins by a SV40 large T fragment
restores T-loop phosphorylation of CDK2 and CDK1 despite
genetic inactivation of CDK7 [74]. That observation too shows
the existence of non-CDK7 CAKs in mammalian cells. Second, in
our experiments, the requirement for CDK7 activity appears to be
restricted to p21-bound CDK4 (or S178P CDK6). One possible
explanation is that p21 binding might be required to co-localize
CDK4 in the nucleus with CDK7, the CAK activity of which
depends on its nuclear targeting [76]. Outside the nucleus, ectopic
cyclin D3-CDK4 and S178P CDK6 (which are mostly cytoplas-
mic [33]) might be phosphorylated by other proline-directed
kinase(s). Third, the requirement for CDK7 activity is complex
and at least in part indirect. For example, it might be mediated by
CDK2 and CDK4 activation and thus by S130 phosphorylation of
cyclin D/CDK4-bound p21, as discussed below. Though the rapid
effect of CDK7 inhibition on CDK4 phosphorylation indicates a
direct involvement, it does not formally demonstrate it because
CDK7 might conceivably act on other CDK4 kinases (or
phosphatases). Fourth, CDK7 could still be the catalytic subunit
of the regulated proline-directed CDK4-activating kinase that we
postulated [33]. In vitro, cyclin H-CDK7-Mat1 phosphorylates
CDK4 independently of its +1 proline [33], and when coimmu-
noprecipitated from various cell lysates, it is constitutively active
(even when assayed on CDK4) [35–37] (Figure S10). Nevertheless,
CDK7 might act differently in cells due to interaction with
unknown accessory proteins that might not be preserved in CDK7
Figure 9. Model assembling the present observations with previous knowledge [6,10,37,53,61,62]. CDK7 inhibition reveals novel
positive feedbacks mediated by S130 phosphorylation of p21, which is catalyzed by active CDK4 and CDK2 to permit T172 phosphorylation and
activation of CDK4 complexes stabilized by p21 binding. S130 phosphorylation of p21 thus amplifies CDK4 activation and subsequently leads to
increased degradation of p21, which in turn facilitates CDK2 activation. Those retrocontrols of CDK4 activation should contribute to explaining the
irreversibility of the cell cycle commitment at the R point. Green/red colors indicate a final positive/negative influence on R point passage. 1, 2, two
different levels of CDK7 action demonstrated by the present observations. CDK4 AK?, hypothetical CDK4-activating kinase(s) phosphorylating p21-
unbound CDK4 and S178P CDK6 during CDK7 inhibition.
doi:10.1371/journal.pgen.1003546.g009
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immunoprecipitations. Such regulated accessory proteins might
mediate the complex regulations of CDK4 phosphorylation,
including its differential regulation in cyclin D1 and cyclin D3
complexes [36,47]. Even the possibility that CDK7 would not
utilize cyclin H to activate CDK4 in cells cannot be excluded.
Involvement of S130 phosphorylation of p21 in CDK4
activation and cell cycle progression
The S130 phosphorylation site of p21 is not conserved in p27
and p57. Nevertheless, S130 phosphorylation of p21 has been
proposed [62] as the functional homologue of T187 phosphory-
lation of p27 [12,77] and T310 phosphorylation of p57 [78]. S130
phosphorylation of p21 has been reported to be similarly catalyzed
by CDK2 to form a phosphodegron recognized by the SCF/Skp2
ubiquitin ligase complex and to signal the proteasomal degrada-
tion of cyclin/CDK-bound p21 required for S-phase entry [61–
63]. It was also found to be essential for release of a p21-imposed
G1 arrest [79]. Here we show for the first time that this
phosphorylation is abundant in total and CDK4-bound p21
during G1 phase, indicating that it does not rapidly lead to p21
degradation at this stage, possibly because Skp2 levels are kept low
in G1 by proteasomal degradation initiated by APCCdh1 [63].
Whereas most active cyclin D-CDK4 complexes are associated
with p21 in G1-phase HCT116 cells, CDK7 inhibition reduced
S130 phosphorylation and further increased or stabilized the
binding of p21 to these complexes. In agreement with previous
reports, such increased stoichiometry [10,80], and/or stability [9],
of p21 binding is likely sufficient to explain the impaired T172
phosphorylation and activity of CDK4 complexes and their
refractoriness to in vitro activation by CAK. Mutations of the S130
residue and in vitro phosphorylation indeed suggested that this
phosphorylation can reduce the stoichiometry or stability of p21
binding to CDK4 complexes, resulting in increased T172
phosphorylation of p21-bound CDK4. Interestingly, T187 phos-
phorylation of p27 also facilitates its release from cyclin E-CDK2
complexes [77]. At later time points, inhibition of S130
phosphorylation likely also explains the increased accumulation
of p21 in response to CDK7 inhibition, in agreement with
previous studies [61–63]. This too might suffice to prevent
phosphorylation and activation of CDK4 complexes, as observed
in response to proteasome inhibition by MG132.
There are no crystallographic or biophysical data to explain
how cyclin D-CDK4 complexes might possibly accommodate
more than one p21 molecule, and thus how this might be affected
by S130 phosphorylation. p21 is an intrinsically unstructured,
flexible protein containing two cyclin- and one CDK-binding
domain [64,71]. In the case of cyclin D1-CDK4, the interaction of
p21 with CDK4 and the resulting inhibition of its activity have
been reported to depend mainly on both the N-terminal Cy1
cyclin-binding motif and the K CDK-binding site [64,81].
However, the involvement of the C-terminal Cy2 cyclin-binding
site is unclear. Whereas a Cy2 peptide is unable to affect the cyclin
D1-CDK4-p21 interaction, a longer peptide containing residues
127 to 164 of p21 (thus encompassing both the Cy2 and S130)
efficiently blocks the p21 interaction [64]. Therefore, further
experiments should investigate if the S130 residue is directly
involved in the interaction of p21 in such a way that the
phosphorylation of this site would alter the p21 inhibitory activity.
The p21 S130 residue can be phosphorylated by cyclin E-
CDK2 [61,62] and also by CDK6 activated by the viral cyclin K
[79]. Using 2D gel separations, we show that the in vitro
phosphorylation of p21 by cyclin E/A-CDK2 occurs mainly at
S130 but also at S98 (a residue reported to be phosphorylated by
ASK1 and JNK1 but not CDKs [82]), and we show for the first
time that cyclin D-CDK4/6 also readily phosphorylate S130. Like
p27 in cyclin E-CDK2 complexes [12], p21 is thus both a potential
inhibitor and a substrate of cyclin D-CDK4/6 complexes.
Interestingly, S130 was more efficiently phosphorylated by the
different CDK complexes when p21 was bound to cyclin D-
CDK4. This, together with two other observations, suggests that
p21 is not phosphorylated merely via an autonomous ‘‘intra-
complex’’ mechanism. First, binding to inactive CDK4 complexes
similarly increased the S130 phosphorylation of p21 in transfected
CHO cells (Figure 4C). Second, S130 phosphorylation did not
appear after incubation of p21-cyclin D3-CDK4 complexes with
high ATP concentrations but no other kinase (Figure 3B). p21 as a
subunit of the CDK4 complex would thus be phosphorylated, and
hence regulated, by other active CDK4 and CDK2 complexes. As
for CDK2-dependent phosphorylation of p21 on S130 in vitro [61],
deletion of the C-terminal Cy2 cyclin-binding site much reduced
p21 phosphorylation in HCT116 cells (Figure S11), suggesting that
in cyclin D/CDK4-bound p21 the interaction with other active
cyclin-CDK complexes to phosphorylate S130 is mediated by the
Cy2 site. In intact HCT116 and CHO cells, the involvement of
both CDK4 and CDK2 in S130 phosphorylation was further
established by its inhibition in response to increased p21
expression, inhibition of CDK4/6 by PD0332991, and/or
inhibition of CDKs by roscovitine and CR8 (which do not
directly inhibit CDK4 activity). CR8 did not inhibit CDK7
activity in these experiments and thus most likely acted by
inhibiting CDK2. In all those situations, much reduced T172
phosphorylation and activity of p21-bound CDK4 were associated
with the inhibition of p21 S130 phosphorylation. To our
knowledge, this is the first indication that CDK2 might control
CDK4 activation.
Our data suggest that, depending on their activities during cell
cycle progression, either CDK4 or CDK2 complexes can exert
positive feedbacks to reduce the negative impact of p21 on CDK4
activation (Figure 9). This could further amplify CDK4 activation
and subsequently lead to increased degradation of p21, which in
turn facilitates CDK2 activation. Our data indicate that p21
inhibitory activity can be deactivated inside the inhibited cyclin D-
CDK4 complex by other active CDK4 complexes. If this can be
verified, theoretical conditions would be met to generate a bistable
biochemical system (see e.g. [83] for a mathematical discussion of
the analogous deactivation of p27 by cyclin E-CDK2). In such a
switch-like biochemical module, binary (all-or-none) activation of
CDK4 could occur, and sustain its permissiveness to activation
despite reduced mitogenic stimulation, once the threshold barrier
imposed by the p21 inhibitory potential has been overcome [84].
The positive ‘‘reverse’’ feedback pathways from CDK4 and
CDK2 to CDK4 activation proposed here for the first time would
introduce the notion that not only the pRb-E2F switch [5], but
also its trigger, might be endowed with bistable properties that
would contribute to explaining the irreversibility of the cell cycle
commitment at the R point. This mechanism (or similar ones in
p21-independent CDK4 activation as observed in cAMP-depen-
dent cell cycle of thyrocytes [39,85]) can explain the exceptional
robustness of the correlation between CDK4 T172 phosphoryla-
tion, pRb phosphorylation and subsequent S-phase entry that we
have observed in all the cell models and regulations we studied.
A future challenge will be to identify the mechanisms that
engage the positive feedback amplifying system that we suggest
here for the activation of CDK4 complexes stabilized by p21,
which represent the bulk of CDK4 complexes in G1 phase.
Mitogenic signal transduction kinases might directly phosphorylate
the p21 S130 residue [86]. However, this possibility is not
supported by the disappearance of S130 phosphorylation associ-
CDK7/CDK4/CDK2/p21 Interplay at R Point
PLOS Genetics | www.plosgenetics.org 15 May 2013 | Volume 9 | Issue 5 | e1003546
ated with CDK inhibition. Alternatively, less stable but very active
cyclin D-CDK4 complexes exist without binding to p21 or p27
[31,58–60], the activation of which would depend on yet unknown
non-CDK7 activating kinases as suggested here. Our in vitro
experiments (Figure S6) raise the interesting possibility that a
minimal amount of such hyperactive p21/p27-unbound CDK4
complexes might initiate the autocatalytic activation of a
significant proportion of p21-bound CDK4 complexes through
S130 phosphorylation (acting as kindling to ignite the pyre) (Figure 9).
CDK4 phosphorylation as a convergent target of cancer
therapies
The corollary of the central position of T172-phosphorylation of
CDK4 in the cell cycle decision module is its responsiveness to
various drugs or treatments used or envisaged in cancer therapy.
CDK4 phosphorylation is a central node integrating oncogenic
signaling cascades, as its abrogation requires combined inhibition of
the Ras/MEK/ERK and mTOR pathways [37]. But amazingly, it
is also inhibited by various CDK inhibitors that were not suspected
to affect CDK4 activity, including roscovitine (Seliciclib), and drugs
that increase p21 levels, including proteasome inhibitors, such as
Bortezomib. In p53-proficient cells, genotoxic therapeutic drugs and
treatments, which induce large amounts of p21, are thus also
expected to inhibit CDK4 phosphorylation. The resulting inhibition
of CDK4 activity may halt cell proliferation in pRb-proficient
tumors. On the other hand, p21-dependent inhibition of CDK4
activation might also explain the stronger resistance of pRb-
proficient cells to the apoptotic effect of these different treatments,
which might be exploited to protect normal cells and hence allow
more aggressive treatments of pRb-deficient tumors [29,87]. Finally,
the novel positive feedback pathways identified here from CDK4
and CDK2 to facilitate CDK4 activation may explain the relative
resistance to receptor or cell signaling kinase inhibitory drugs of
cancer cells that have intrinsically strong CDK4 activity (e.g. due to
frequent CDKN2A deletion or Cdk4 amplification) and/or CDK2
activity (e.g. due to deregulation of cyclin E). This would provide a
rationale for treatments that combine inhibitory drugs targeting
oncogenic signaling pathways and CDKs, as suggested recently [88].
Materials and Methods
Cell culture, BrdU incorporation, and transfection
These procedures were preformed exactly as described [33,53].
p21-null HCT116 cells were provided by Vogelstein Lab (Baltimore).
After starvation without FBS for 3 days, HCT116 cells were growth-
stimulated with 10% FBS. Inhibitors were dissolved in DMSO and
used at the following final concentrations: 20 mM roscovitine (Sigma),
10 mM 1-NMPP1 (Santa Cruz Biotechnology), 250 nM or 1 mM
PD0332991, as indicated in figures legends (Selleck Chemicals),
0.5 mM CR8 (kind gift from Laurent Meijer, or Sigma), 10 mM
MG132 (Calbiochem). Vehicle (0.2% DMSO) was added in the
controls. DNA replicating cells were identified by 30-min incubation
with BrdU. The incorporation of BrdU was detected by immuno-
fluorescence: BrdU-labeled nuclei were counted as described [36].
CHO and HCT116 cells were transfected in 9-cm Petri dishes for
48 h or 24 h, respectively, using Fugene (Roche Diagnostics) with
6 mg of pcDNA6 vector encoding HA-tagged CDK4 and Xpress-
cyclin D3, and 6 mg or 0.6 mg pE vectors encoding human p21 and its
mutants. All constructs were verified by sequencing.
Lentivirus production, cell infection and selection
HEK293T cells were transfected by calcium phosphate for 6 h
with a mix of vectors: pSPAX2, pMD2G (Trono Lab),
pDG2iV5puro encoding N-terminus 36HA-tagged human p21
or its mutants, or pLVX-rtTA3 (TetON) or Tight-puro (Clontech)
encoding Flag tagged CDK6 wt, CDK6 S178P mutant or cyclin
D3. Multi-cistronic pDG2iV5puro is a modified version of the
pLenti6 V5/DEST vector (Invitrogen). It contains an expression
cassette under the control of a Tet-responsive element allowing
doxycycline-inducible expression of the gene of interest and an
SV40 promoter controlling rtTA3 transactivator expression
followed by an IRES and a puromycin-resistance marker.
Transfected HEK293T supernatant was collected after 2 days,
clarified, filtered, and concentrated on Amicon filter (Millipore).
HCT116 cells were infected for 24 h by adding to the culture
medium a volume of lentiviruses corresponding to 100 mg of p24
capsid protein per 506103 cells (titrated by ELISA according to
the manufacturer’s protocol, INNOTEST HIV Antigen mAb,
Innogenetics). Infected cells were selected by antibiotic resistance
with a final concentration of 0.4 mg/ml of puromycin (Invivogene).
Immunoprecipitation, pRb-kinase assay, and 2D gel
electrophoresis
(Co-)Immunoprecipitations were performed as described
[31,89] using the following antibodies : monoclonal antibodies
against cyclin D1 (DCS-11) or cyclin D3 (DCS-28) (all from
Neomarkers); monoclonal antibody against HA epitope (F7) and
polyclonal antibodies against p21 (C-19), CDK6 (C-21), CDK7
(C-19) and cyclin H (C-18) (all from Santa Cruz Biotechnology);
monoclonal anti-Flag (M2) (Sigma).
To assay pRb-kinase activity, immunoprecipitated protein
complexes were incubated with ATP and a recombinant pRb
fragment (QED or Sigma). The mixture was then separated by
SDS-PAGE and western blotted to detect T826 phosphorylation
of the pRb fragment and co-immunoprecipitated proteins [31,89].
For 2D gel electrophoresis, separations were performed exactly as
described [31,33,41], and the immunoprecipitations were dena-
tured in a buffer containing 7 M urea and 2 M thiourea. Proteins
were separated by isoelectric focusing on immobilized linear pH
gradient strips (pH 3 to 10) and then separated by SDS-PAGE and
immunoblotted.
In vitro phosphorylation
Complexes containing CDK4 or CDK6 from HCT116 cells,
p21 from CHO cells transfected with p21 vector alone, or with
cyclin D3 or cyclin D1-Flag and CDK4 vectors, or HA-p21 from
stably infected HCT116 K7AS by lentiviruses expressing inducible
36HA-p21 wt or its mutants were immunoprecipitated and used
as substrate for in vitro phosphorylation. When indicated,
immunoprecipitates were first dephosphorylated with l-phospha-
tase as described [33]. The immunoprecipitates were washed three
times with NP40 buffer (150 mM NaCl, 50 mM Tris-HCl,
pH 7.5, 0.5% Nonidet P-40, 50 mM NaF, 1 mM sodium
orthovanadate, 1 mM DTT, protease inhibitors (pefablock and
leupeptin) and once with CAK buffer (80 mM b-glycerophos-
phate, pH 7.3, 15 mMMgCl2, 20 mM EGTA, 5 mM DTT). The
beads were resuspended in 50 ml of CAK buffer containing
protease and phosphatase inhibitors and 2 mM ATP and
incubated at 30uC for 1 h with or without 1 mg of recombinant
kinases: CDK2-cyclin E1, CDK2-cyclin A2 and CDK4-cyclin D3
(Carna Biosciences); cyclin H-CDK7-MAT1 (Upstate); CDK4-
cyclin D1 and CDK6-cyclin D1 (ProQinase) .
CAK activity assay
Cyclin D3-CDK4 complexes from transfected CHO cells were
immunoprecipitated and dephosphorylated with l-phosphatase as
described [33]. These complexes were used as a substrate for
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activation by CAK complexes immunoprecipitated from HCT116
K7AS cells. Their in vitro activation was then assessed by their
pRb-kinase activity [36]. Dephosphorylated cyclin D3-CDK4
complexes were washed three times with NP-40 lysis buffer and
then three times with CAK buffer. The beads were mixed in 30 ml
of CAK buffer containing protease and phosphatase inhibitors
with cyclin H-CDK7 complexes (coimmunoprecipitated using the
C-18 cyclin H antibody) from K7AS cells either treated or not
treated with FBS or CR8. After addition of 1 mM ATP, the
suspensions were incubated at 30uC for 30 min. After three washes
in CAK buffer and three washes in pRb kinase buffer, the
immunoprecipitated proteins were assayed for pRb kinase activity
as described above.
Immunoblot analysis
SDS-PAGE separations of equal amounts of whole cell extract
proteins [89], and immunoprecipitates were immunodetected
using the following antibodies: monoclonal antibodies against
cyclin D1 (DCS-6), cyclin D3 (DCS-22), p27 (DCS-72), p21
(DCS60) (all from Neomarkers); monoclonal antibody anti-cyclin
E (HE12) (Pierce Biotechnology); monoclonal anti-cyclin A E43.2
(kind gift from Tim Hunt); anti-total pRb monoclonal antibody
(#554136, BD Pharmingen); polyclonal anti-phospho-pRb anti-
bodies (T826 and T821) (Biosource-Invitrogen); polyclonal anti-
bodies anti-phospho-pRb (S807/811), anti-phospho-CDK2
(T160), anti-phospho-histone H3 (S10) (all from Cell Signaling
Technology); monoclonal antibody against HA epitope (F7),
CDK7 (C-4) and MAT1 (F-6), polyclonal antibodies against
CDK4 (C-22), CDK6 (C-21), CDK2 (M-2), cyclin H (C-18),
phospho-CDK7 (T170), XPD (TFIIH p80) (all from Santa Cruz
Biotechnology); monoclonal antibodies against total RNA Poly-
merase II (8WG16), phospho-Ser2 (H5) or phospho-Ser5 (H14) of
RNA Polymerase II (all from Covance). Secondary antibodies
were either coupled to horseradish peroxidase (Amersham
Biosciences) for detection by enhanced chemiluminescence (West-
ern Lightning, Perkin-Elmer) or to DyLight 680 and 800 (Pierce
Biotechnology) for infrared fluorescence detection using the
Odyssey scanner (LI-COR).
Supporting Information
Figure S1 (Related to Figure 1). Characterization of DNA
synthesis (A), cell cycle protein levels (B) and CDK4 phosphory-
lation during cell cycle progression in HCT116 K7AS cells.
HCT116 WT (A) or K7AS (A–C) cells were synchronized by
serum deprivation for two days and re-stimulated with 10% fetal
bovine serum (FBS) for different times. (A) DNA synthesis was
evaluated from duplicate dishes by counting the percentage of cells
having incorporated BrdU during the last 30 min of stimulation.
(B) Western blotting analysis was performed with the indicated
antibodies from whole-cell lysates. *, pRb hypophosphorylated
band; **, pRb hyperphosphorylated bands. (C) Cell lysates were
immunoprecipitated (IP) with anti-cyclin D1 (D1) or anti-cyclin
D3 (D3) antibodies and separated by 2D gel electrophoresis
followed by CDK4 detection. Arrows, T172-phosphorylated form
of CDK4. Different exposures are shown for the different time
points to better visualize the proportion of the CDK4 phosphor-
ylated form irrespective of the relative amount of cyclin D-CDK4
complexes. In K7AS HCT116 (K7AS), DNA synthesis started to
increase between 6 and 8 h after stimulation and peaked at 12–
16 h (Figure S1A). As readout of CDK4 and CDK6 activity, T826
phosphorylation of pRb was first observed to increase at 3 h and
peaked at 16 h (Figure S1B). Cyclin D1 and cyclin D3 expression
was first seen to increase at 2 h. Whereas cyclin D1 accumulation
peaked at 6 h, cyclin D3 continued to accumulate during S and
G2 phases until 24 h. CDK4 and CDK6 expression was much less
modulated (Figure S1B). Interestingly, the phosphorylation of
cyclin D1-bound CDK4 appeared at 2–3 h into G1 phase,
whereas the phosphorylation of cyclin D3-bound CDK4 was
already detected in serum-deprived cells and further increased
much later at 12 h and subsequent time points, when most cells
were in S-G2 phases (Figure S1C). This suggests that CDK4
complexed to cyclin D1 and cyclin D3 might have partially
different roles in the different cell cycle phases. The activating
T160 phosphorylation of CDK2 was observed to increase at 4–
6 h, along with an increased accumulation of cyclin E and a
migration shift of this protein (likely associated with its CDK2-
dependent phosphorylation [90]). This coincided with the partial
disappearance of p21 and p27, which reappeared at later time
points (20–24 h) (Figure S1B).
(TIF)
Figure S2 (Related to Figure 1). Specific inhibition of CDK7 by
1-NMPP1 prevents T826 phosphorylation of pRb and T160
phosphorylation of CDK2 while increasing p21 accumulation (A).
Specific inhibition of CDK7 also prevents the activating
phosphorylation (B) and pRb-kinase activity of CDK6 (C). WT
(A) and K7AS (A–C) HCT116 cells were stimulated (+) or not
stimulated (2) with fetal bovine serum (FBS) for the indicated
times in the absence (2) or presence (+) of 1-NMPP1. (A) Western
blotting analysis with the indicated antibodies from whole-cell
lysates. (B,C) Cell lysates (analyzed in Figure 1B–1D) were
immunoprecipitated (IP) with anti-cyclin D1 (D1) or anti-cyclin
D3 (D3) and separated by 2D gel electrophoresis followed by
CDK6 immunodetection (B), or were immunoprecipitated with
anti-CDK6 antibody, assayed for pRb-kinase activity, separated
by SDS-PAGE, and immunoblotted with the indicated antibodies
(C). Arrows, position of the T177-phosphorylated form of CDK6.
(TIF)
Figure S3 Unlike cyclin D3-CDK6, CDK4 complexes from
CDK7-inhibited cells are refractory to in vitro phosphorylation by
CAK. HCT116 K7AS cells were stimulated (+) or not stimulated
(2) with fetal bovine serum (FBS) for 5 h in the absence (2) or
presence (+) of 1-NMPP1. Cell lysates were immunoprecipitated
(IP) with anti-cyclin D1 (D1), anti-cyclin D3 (D3) or anti-p21
antibodies and incubated with ATP in the presence (+) or absence
(2) of recombinant cyclin H-CDK7-MAT1 complex (CAK). The
complexes were then separated by 2D gel electrophoresis and
immunodetected with a mixture of anti-CDK4 and anti-CDK6
antibodies. In the inset, as a positive control of CAK activity in the
same experiment, immunoprecipitated (D3 IP) cyclin D3-CDK4
complexes from CHO cells transfected with plasmids encoding
cyclin D3 and CDK4-HA were pretreated or not with l-
phosphatase (l PPase) and then incubated with ATP with or
without CAK, before 2D gel electrophoresis and CDK4
immunodetection. Arrows indicate the position of T172/T177-
phosphorylated form of CDK4/6. If the impaired activation of
CDK4 and CDK6 complexes in CDK7-inhibited K7AS cells was
due only to absence of activating phosphorylation, these
complexes should remain phosphorylatable by CAK in vitro, as
observed here using cyclin D3-CDK4 complexes produced in
CHO cells (inset). By contrast, only cyclin D3-CDK6, but neither
cyclin D3-CDK4, cyclin D1-CDK4 nor cyclin D1-CDK6, was
phosphorylated by CAK from 1-NMPP1-treated cells. This
refractoriness to CAK activation of cyclin D3-CDK4 from
CDK7-inhibited cells might have been due to its increased
association with p21 (Figure 1C). Indeed, p21-bound CDK4 and
CDK6 (which in part were associated with cyclin D3) from
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CDK7-inhibited cells were also refractory to phosphorylation by
CAK. Consistently, the observation that only cyclin D3-CDK6
but not cyclin D3-CDK4 from CDK7-inhibited cells could be
activated by CAK is likely explained by the weaker binding, and
hence relative resistance, of cyclin D3-CDK6 complexes to p21
[91]. Unexpectedly, irrespective of the cell treatment by serum or
1-NMPP1, none of the cyclin D1 complexes could be re-activated
by CAK in these experiments. Others have also observed that only
cyclin D3-CDK6 but neither cyclin D1-CDK6 nor cyclin D1-
CDK4 could be activated by CAK in vitro [32]. As T-loop
phosphorylation of CDK7 might be more important for its
recognition of S/T-P motifs (as found in CDK4 and most non-
CDK substrates of CDK7) [92], we also verified that the
recombinant CDK7 was largely phosphorylated at T170 using
2D-gel electrophoresis combined with a T170-phosphospecific
antibody (data not shown).
(TIF)
Figure S4 (Related to Figure 3A). (A) As in Figure 3A, HCT116
K7AS cells were stimulated (+) or not stimulated (2) with fetal
bovine serum (FBS) for 5 h in the absence (2) or presence (+) of 1-
NMPP1. Cell lysates were immunoprecipitated with anti-p21
antibody and separated by 2D gel electrophoresis followed by p21
immunodetection. This strong exposure allows observation of the
doubly phosphorylated form of p21. (B) As in Figure 2, K7AS cells
were stimulated with FBS for 5 h and 1-NMPP1 was added or not
added for 1 h. Cell lysates were immunoprecipitated with anti-
cyclin D1 antibody (D1 IP) and separated by 2D gel electropho-
resis followed by p21 immunodetection. (C) Kinetics of the
appearance of phosphorylated forms of p21 and T172 phosphor-
ylation of p21-bound CDK4 during cell cycle progression.
HCT116 K7AS cells were stimulated or not stimulated with
FBS for the indicated times. Cell lysates were immunoprecipitated
(IP) with anti p21 antibody and separated by 2D gel electropho-
resis followed by CDK4 and p21 detection. Black arrows, T172-
phosphorylated form of CDK4. Different exposures are shown for
the different time points to better visualize the proportion of the
different forms of p21 and CDK4 irrespective of the relative
amounts of p21 and p21-bound CDK4 complexes. Colored
arrows indicate phosphorylated forms of p21 identified by their
characteristic migration and mutagenesis as analyzed in Figure S5
and Figure 3B, 3C.
(TIF)
Figure S5 (Related to Figure 3B, 3C). Identification of the
phosphorylated forms of p21. CHO cells were transfected with
plasmids encoding wild-type p21 (WT) or the indicated mutants of
p21, alone (A) or together with plasmids encoding cyclin D3 and
CDK4-HA (B). Cell lysates were immunoprecipitated (IP) with
anti-cyclin D3 (D3) (B) or anti-p21 antibodies (A) and incubated
with the indicated recombinant kinases and ATP. The proteins
were separated by 2D gel electrophoresis followed by p21
immunodetection. Right panel in (B), superimposition of 2D gel
profiles of WT p21 (colorized in green) and the indicated mutants
of p21 (colorized in red) after phosphorylation by cyclin A-CDK2.
Arrows indicate the main phosphorylated forms of p21.
(TIF)
Figure S6 (Related to Figure 3B, 3C). Binding to cyclin D1-
CDK4 presents p21 for S130 phosphorylation by cyclin D1-
CDK4 and cyclin D1-CDK6. CHO cells were transfected with
plasmids encoding p21 alone (left column) or together with
plasmids encoding cyclin D1-Flag and CDK4-HA (right column).
Cell lysates were immunoprecipitated (IP) with anti-p21 (left) or
anti-Flag antibodies (right) and incubated with ATP and the
indicated recombinant kinases. The proteins were separated by 2D
gel electrophoresis followed by p21 immunodetection. Arrows
indicate the phosphorylated forms of p21.
(TIF)
Figure S7 Proteasomal inhibition increases p21 levels and
mimics the effects of CDK7 inhibition on phosphorylations of
pRb and CDK2 (A), pRb kinase activity (B), and T172
phosphorylation of CDK4 and S130 phosphorylation of p21 (C).
HCT116 K7AS cells were restimulated or not restimulated with
fetal bovine serum (+/2 FBS) during 5 or 16 h in the continuous
absence (2) or presence (+) of MG132. (A) Western blotting
analysis was performed with the indicated antibodies from whole-
cell lysates. (B,C) Lysates from cells treated for 5 h were
immunoprecipitated (IP) with anti-p21 or anti-cyclin D1 (D1)
antibodies and assayed for their pRb-kinase activity, separated by
SDS-PAGE and immunoblotted with the indicated antibodies (B),
or were separated by 2D gel electrophoresis followed by CDK4
and p21 immunodetection (C).
(TIF)
Figure S8 (Related to Figure 5). (A) In the context of K domain
T57D mutation, S130D phosphomimetic mutation of p21
weakens p21 binding to CDK4 and increases phosphorylation of
the remaining CDK4 bound to p21. Stably infected HCT116
K7AS cells for Tet-On inducible 36HA-p21 wt or indicated
mutants were treated with doxycycline (1 mg/ml) for 16 h prior to
cell restimulation with fetal bovine serum (FBS) for 16 h in the
continuous presence of doxycycline. Cell lysates were immuno-
precipitated (IP) with anti-HA antibody and separated by 2D gel
electrophoresis followed by simultaneous immunodetection of
ectopic 36HA-p21 and 36HA-p21-bound endogenous CDK4
using a mixture of anti-CDK4 and p21 antibodies. (B) Phosphor-
ylation of p21 by cyclin A-CDK2 potentially modifies the
interaction of p21 with cyclin D-CDK4 to increase the accessibility
of CDK4 T172 to CAK. Stably infected HCT116 K7AS cells
allowing doxycycline-inducible HA-p21 wt or T57D mutant
expression were serum-deprived for 48 h and treated with
doxycycline (1 mg/ml) during 16 h. Cell lysates were immunopre-
cipitated (IP) with anti-HA (HA) antibody and incubated first with
ATP with or without recombinant cyclin A2-CDK2 and then with
ATP with or without recombinant cyclin H-CDK7-MAT1 (CAK).
The proteins were separated by 2D gel electrophoresis followed by
simultaneous immunodetection of ectopic 36HA-p21 and 36HA-
p21-bound endogenous CDK4 using a mixture of anti-CDK4 and
p21 antibodies. Right panels in (A,B) are CDK4 enlargements
with adjustment of exposure times to facilitate comparison of the
proportion of the phosphorylated form (arrows). Colored arrows in
(B) indicate phosphorylated forms of p21. The experiment in
Figure S8A suggested that S130 phosphorylation of p21 may
somehow weaken its interaction with cyclin D-CDK4 complexes,
allowing CDK4 phosphorylation by CAK or another kinase. As
no previous study has reported that S130 phosphorylation could
be mimicked by the S130D mutation (unlike the homologous
T187D mutation of p27), we wanted to evaluate whether in vitro
phosphorylation of p21-cyclin-CDK4 complexes by CDK2 might
more efficiently affect them and the capacity of p21-bound CDK4
to be phosphorylated by CAK. As shown in Figure S8B,
codetection of p21 and CDK4 after in vitro phosphorylation by
cyclin A2-CDK2 and/or CAK revealed that (i) cyclin A2-CDK2
phosphorylated p21 at S130, S98 and another unidentified site
(lane3; as previously observed in Figure 3B). Of note, CAK also
phosphorylated p21 at another unidentified site (not S130, T57 or
S98 as demonstrated by different migration; lane 2); (ii)
phosphorylation of wt p21 by cyclin A2-CDK2 did not affect
CDK4 co-immunoprecipitation and did not appreciably increase
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subsequent phosphorylation of p21-bound CDK4 by CAK (lane
4); (iii) however, in the T57D mutation context, phosphorylation
by cyclin A2-CDK2 much reduced CDK4 interaction with p21
(lane 7), allowing complete phosphorylation by CAK of the
remaining p21-bound CDK4 (lane 8).
(TIF)
Figure S9 (Related to Figure 6). (A) Effect of roscovitine, 1-
NMPP1 and CR8 on RNA polymerase II phosphorylation.
HCT116 K7AS cells were stimulated (+) or not stimulated (2)
with fetal bovine serum (FBS) for 5 h in the absence or presence of
the following inhibitors: roscovitine (rosco), 1-NMPP1, CR8 or a
combination of 1-NMPP1 and CR8. Western blotting analysis was
performed with the indicated antibodies from whole-cell lysates.
To evaluate the impact of R-roscovitine and CR8 on CDK7 in
Figure 6 experiments, we compared their effect to specific
inhibition of CDK7 by 1-NMPP1 on phosphorylations of C-
terminal domain (CTD) of the large subunit of RNA polymerase
II. Previous studies in K7AS HCT116 cells have shown that CTD
S5 phosphorylation is performed by both CDK7 and CDK9,
whereas CTD S2 might be an exclusive CDK9 substrate [53,93].
As previously shown [53], CDK7 inhibition by 1-NMPP1 was
insufficient to affect CTD S5 and S2 phosphorylations. By
contrast, roscovitine inhibited both phosphorylations, whereas
CR8 inhibited only, but completely, S2 phosphorylation, con-
firming its inhibitory impact on CDK9 [94]. Interestingly, 1-
NMPP1 did abrogate S5 phosphorylation in the presence of CR8
(A). This confirmed that inhibition of CTD S5 phosphorylation
requires combined inhibition of both CDK7 and CDK9, and also
implies that CR8 did not affect CDK7 activity. Overall, we
concluded that, in addition to strong CDK2 inhibition, roscovitine
reduced CDK7 and CDK9 activities, whereas CR8 inhibited
CDK2 and CDK9 but not CDK7. Effect of roscovitine on
phosphorylations of p21 and CDK4 thus most likely resulted from
inhibition of both CDK2 and CDK7, whereas CR8 acted only
through CDK2 inhibition. (B) The effect of CDK2 inhibition by
CR8 on CDK4 phosphorylation is delayed compared to its abrupt
disappearance resulting from CDK7 inhibition. HCT116 K7AS
cells were stimulated with fetal bovine serum (FBS) for 5 h and
roscovitine (rosco), CR8 or 1-NMPP1 were added or not added for
1 h. Cell lysates were immunoprecipitated (IP) with anti-cyclin D1
(D1), anti-cyclin D3 (D3) or anti-p21 antibodies and separated by
2D gel electrophoresis followed by CDK4 immunodetection.
(TIF)
Figure S10 (Related to Figure 6C). Serum stimulation and
CDK2 inhibition by CR8 in HCT116 K7AS cells has little effect
on the composition and activity of CAK (cyclin H-CDK7-MAT1)
complexes (A) and phosphorylation profile of CDK7 (B). (A,B)
K7AS cells were stimulated or not stimulated (cont) with fetal
bovine serum (FBS) for 5 h in the absence or presence of CR8 as
in Figure 6C. (A) The activity of co-immunoprecipitated cyclin H-
CDK7 complexes (cyc H IP) from these cells was evaluated on
CDK4 complexes used a substrate. In this assay, these cyclin H-
CDK7 complexes were mixed and incubated with ATP and
inactive (dephosphorylated by l-phosphatase) cyclin D3-CDK4-
HA complexes produced and immunoprecipitated from transfect-
ed CHO cells [33]. The resulting activation of the cyclin D3-
CDK4-HA complexes was then assayed by their pRb-kinase
activity. The mixtures were separated by SDS-PAGE and
immunoblotted. We detected cyclin H (cyc H) and CDK7,
T170-phosphorylated CDK7, MAT1 and XPD co-immunopre-
cipitated by the cyclin H antibody from K7AS cells, and the
presence of the substrate, i.e. cyclin D3-CDK4-HA complexes
from CHO cells (CDK4-HA), and its in vitro activation reflected by
the T826 phosphorylation of the pRb fragment (pRb-kinase). (B)
Phosphorylation profiles of CDK7. Same cell lysates as in (A) were
immunoprecipitated (IP) with anti-CDK7 or anti-cyclin H (cyc H)
and separated by 2D gel electrophoresis followed by immunode-
tection by antibodies directed against CDK7 or T170-phosphor-
ylated CDK7 (P-CDK7 (T170)). As deduced from computed
isoelectric points [40] and detection by the T170-phosphospecific
antibody, arrowheads and arrows indicate singly and doubly
phosphorylated CDK7 forms, respectively. The doubly phosphor-
ylated forms are most likely phosphorylated at both T170 and
S164 [51].
(TIF)
Figure S11 Phosphorylations of p21 and p21-bound CDK4
depend on the Cy2 cyclin-binding motif of p21. Stably infected
HCT116 K7AS cells for Tet-On inducible 36HA-p21 wt or DCy2
(aa 1 to 154) mutant were treated with doxycycline (1 mg/ml) for
16 h prior cell restimulation with fetal bovine serum (FBS) for 16 h
in the continuous presence of doxycycline. Cell lysates were
immunoprecipitated (IP) with anti-HA antibody and separated by
2D gel electrophoresis followed by simultaneous immunodetection
of ectopic 36HA-p21 and 36HA-p21-bound endogenous CDK4
using a mixture of anti-CDK4 and p21 antibodies. Black arrow,
T172-phosphorylated CDK4. Colored arrows indicate phosphor-
ylated forms of p21. Black arrowheads indicate the unpho-
sphorylated form of wt and DCy2 p21. Of note, deletion of the 10
C-terminal aminoacids (including the Cy2 motif) much modifies
the isoelectric point of p21 (computed isoelectric points of 36HA-
p21 and its DCy2 mutant are 7.63 and 5.61, respectively). This
explains why the phosphorylated forms are much less separated in
the DCy2 mutant, which also precludes the formal identification of
these forms (the form indicated by a blue arrow is putatively
phosphorylated on S98).
(TIF)
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